Results 131 to 140 of about 1,804 (172)
Some of the next articles are maybe not open access.
A closer inspection of tedizolid
The Lancet Infectious Diseases, 2015I read the Article by Gregory Moran and colleagues, who used intention to treat (ITT) analysis of a noninferiority trial, with great interest. ITT is widely accepted as the appropriate analysis for randomised controlled trials. However, this recognition is based on assumptions of trial design. Superiority trials (ie, the attempt to prove treatment A is
openaire +4 more sources
Tedizolid: A new oxazolidinone antimicrobial
American Journal of Health-System Pharmacy, 2014The mechanism of action, pharmacokinetics, pharmacodynamics, and clinical efficacy and safety of an investigational second-generation oxazolidinone are reviewed.Tedizolid is a protein synthesis inhibitor in clinical development for the treatment of gram-positive infections.
Kisgen, Jamie J. +3 more
openaire +3 more sources
Long-term use of tedizolid for pulmonary nocardiosis
Journal of Infection and Chemotherapy, 2022Nocardiosis usually occurs in immunocompromised patients and causes infections in various organs, including the lungs, skin, and organs of the central nervous system. Herein, we report the case of a patient with minimal change nephrotic syndrome who had been on immunosuppressive drugs and developed pulmonary nocardiosis due to Nocardia nova complex and
Yuri Chomei +2 more
openaire +2 more sources
Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab
Journal of the American Pharmacists Association, 2014Antibacterial agents Skin and skin structure infections are most often caused by Grampositive bacteria such as streptococci and staphylococci. The number of these infections that are caused by methicillin-resistant Staphylococcus aureus (MRSA) has rapidly increased in recent years in both the community and hospital settings.
Daniel A, Hussar, Angelique, Nguyen
openaire +2 more sources
177Lutetium-Tedizolid for Imaging and Treatment of Infection
2022Enfeksiyon hastalıkları hala dünyada temel sağlık problemlerinden birini oluşturmaktadır. Enfeksiyonun erken aşamalarda teşhisi ve kanser veya inflamasyon gibi diğer patolojilerden ayrımı, enfeksiyonu akut aşamalarda tedavi etmede kritik rol oynamaktadır.
KARPUZ, Merve +3 more
openaire +2 more sources
The role of tedizolid in skin and soft tissue infections
Current Opinion in Infectious Diseases, 2018Purpose of review Tedizolid is a second-generation oxazolidinone with activity against Gram-positive bacteria, including MRSA isolates resistant to linezolid. Pivotal clinical trials showed that tedizolid at 200 mg once-daily for 6 days is not inferior to linezolid 600 mg twice daily for 10 days in patients with SSTI.
Emilio, Bouza +2 more
openaire +2 more sources
Tedizolid: a service evaluation in a large UK teaching hospital
European Journal of Clinical Microbiology & Infectious Diseases, 2020Tedizolid is a new oxazolidinone antibiotic with little real-life data on use outside of skin and soft tissue infections. There is a paucity of safety evidence in courses greater than 6 days. Our centre uses tedizolid predominantly when linezolid-associated adverse events have occurred. This service evaluation describes our experience to date.
Joshua A. York +7 more
openaire +2 more sources
Tedizolid for osteoarticular infections: Evaluation of the published evidence
European Journal of PharmacologyTedizolid phosphate, an oxazolidinone antibiotic, has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). However, its off-label use has been reported in various infections, including osteoarticular infections.A systematic review of data from PubMed, Scopus, and Web of Science was conducted to evaluate the ...
Veatriki Athanasiou +4 more
openaire +2 more sources